Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

被引：25

作者：

Diefenbach, Catherine S. ^{[1
]}

Connors, Joseph M. ^{[2
]}

Friedberg, Jonathan W. ^{[3
,4
]}

Leonard, John P. ^{[5
]}

Kahl, Brad S. ^{[6
]}

Little, Richard F. ^{[7
]}

Baizer, Lawrence ^{[8
]}

Evens, Andrew M. ^{[9
,10
]}

Hoppe, Richard T. ^{[11
]}

Kelly, Kara M. ^{[12
]}

Persky, Daniel O. ^{[13
]}

Younes, Anas ^{[14
]}

Kostakaglu, Lale ^{[15
]}

Bartlett, Nancy L. ^{[6
]}

机构：

[1] NYU, Perlmutter Canc Ctr, 240 East 38th St,19th Floor, New York, NY 10016 USA

[2] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA

[4] Univ Rochester, Med Ctr, Div Hematol Oncol, Rochester, NY 14642 USA

[5] Weil Cornell Univ, Dept Med, New York, NY USA

[6] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA

[7] Tufts Univ, Sch Med, Div Canc Treatment & Diag, Boston, MA 02111 USA

[8] Tufts Univ, Sch Med, Coordinating Ctr Clin Trials, Boston, MA 02111 USA

[9] Tufts Univ, Sch Med, Tufts Canc Ctr, Boston, MA 02111 USA

[10] Tufts Univ, Sch Med, Div Hematol Oncol, Boston, MA 02111 USA

[11] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA

[12] Columbia Univ, Div Pediat Hematol Oncol Stem Cell Transplant, Med Ctr, New York, NY USA

[13] Univ Arizona, Ctr Canc, Dept Med, Tucson, AZ USA

[14] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[15] Mt Sinai Hosp, Dept Radiol, New York, NY 10029 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2017年 / 109卷 / 04期

基金：

美国国家卫生研究院;

关键词：

REED-STERNBERG CELLS; EPSTEIN-BARR-VIRUS; INTERNATIONAL PROGNOSTIC SCORE; INVOLVED-FIELD RADIOTHERAPY; TUMOR-ASSOCIATED MACROPHAGES; COOPERATIVE-ONCOLOGY-GROUP; RADIATION-THERAPY; BRENTUXIMAB VEDOTIN; PHASE-II; DEFINED SUBGROUPS;

D O I：

10.1093/jnci/djw249

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

引用

页数：12

共 50 条

[31] Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies
Christopher G. England
Lixin Rui
Weibo Cai
European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 517 - 532
[32] Hodgkin Lymphoma: First line therapy (focus on early unfavorable disease) - recommendations in the light of current literature
von Tresckow, B.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 6 - 6
[33] Employment and insurance status in Hodgkin lymphoma survivors
Chen, A. B.
Feng, Y.
Neuberg, D.
Recklitis, C.
Diller, L.
Mauch, P.
Ng, A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S138 - S138
[34] The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma
Kwon, J. M.
Park, Y. H.
Kang, J. H.
Kim, K.
Ko, Y. H.
Ryoo, B. Y.
Lee, S. S.
Lee, S. I.
Koo, H. H.
Kim, W. S.
ANNALS OF HEMATOLOGY, 2006, 85 (07) : 463 - 468
[35] Current status of recombinant idiotype vaccines for the treatment of follicular non-Hodgkin's lymphoma
不详
CLINICAL LYMPHOMA, 2002, 3 (03): : 147 - 149
[36] Clinical presentation and staging of Hodgkin lymphoma
Gallamini, Andrea
Hutchings, Martin
Ramadan, Safaa
SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 148 - 154
[37] Predicting the clinical course of Hodgkin lymphoma
Fabbri, Alberto
Gozzetti, Alessandro
Forconi, Francesco
Lauria, Francesco
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (08) : 1 - 1
[38] Predicting the clinical course of Hodgkin lymphoma
Alberto Fabbri
Alessandro Gozzetti
Francesco Forconi
Francesco Lauria
Nature Reviews Clinical Oncology, 2010, 7 : 1 - 1
[39] Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection
Parker, Jayson L.
Zhang, Zoe Yi
Buckstein, Rena
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2011, 14 (02): : 227 - 235
[40] Current role of gemcitabine in the treatment of Hodgkin lymphoma
Oki, Yasuhiro
Younes, Anas
LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 883 - 889

← 1 2 3 4 5 →